BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28881713)

  • 1. Therapeutic vaccine to cure large mouse hepatocellular carcinomas.
    Han Z; Yang D; Trivett A; Oppenheim JJ
    Oncotarget; 2017 Aug; 8(32):52061-52071. PubMed ID: 28881713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.
    Nie Y; Yang D; Trivett A; Han Z; Xin H; Chen X; Oppenheim JJ
    Sci Rep; 2017 Oct; 7(1):14186. PubMed ID: 29079801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harboring TheraVac Elicit Tumor-Specific Immunity for Colon Tumor Treatment.
    Huang Y; Nahar S; Alam MM; Hu S; McVicar DW; Yang D
    ACS Nano; 2023 Oct; 17(20):19740-19752. PubMed ID: 37831945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel modified vaccine (TheraVac
    Masud Alam M; Huang Y; Oppenheim JJ; Yang D
    Cytokine; 2023 Sep; 169():156270. PubMed ID: 37302280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
    Alam MM; Gower T; Jiang M; Oppenheim JJ; Yang D
    J Immunol; 2023 May; 210(9):1428-1436. PubMed ID: 36947147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies.
    Nahar S; Huang Y; Nagy BA; Zebala JA; Maeda DY; Rudloff U; Oppenheim JJ; Yang D
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-cell immunity against the parental tumor.
    Dan Q; Sanchez R; Delgado C; Wepsic HT; Morgan K; Chen Y; Jeffes EW; Lowell CA; Morgan TR; Jadus MR
    Mol Ther; 2001 Nov; 4(5):427-37. PubMed ID: 11708879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma.
    Peng B; Liang L; Chen Z; He Q; Kuang M; Zhou F; Lu M; Huang J
    Hepatogastroenterology; 2006; 53(69):409-14. PubMed ID: 16795983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor.
    Ge L; Zhang JG; Samathanam CA; Delgado C; Tarbiyat-Boldaji M; Dan Q; Hoa N; Nguyen TV; Alipanah R; Pham JT; Sanchez R; Wepsic HT; Morgan TR; Jadus MR
    Cell Immunol; 2009; 259(2):117-27. PubMed ID: 19615673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12.
    Tamaki S; Homma S; Enomoto Y; Komita H; Zeniya M; Ohno T; Toda G
    Clin Immunol; 2005 Dec; 117(3):280-93. PubMed ID: 16246626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synergic effect of adenoviral vector-encoding human alpha-fetoprotein and interferon-gamma on immunity against hepatocellular carcinoma in mice].
    Tan XH; Zhu Q
    Ai Zheng; 2008 Feb; 27(2):155-9. PubMed ID: 18279612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
    Lucas ML; Heller L; Coppola D; Heller R
    Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice.
    Kröger A; Ortmann D; Krohne TU; Mohr L; Blum HE; Hauser H; Geissler M
    Cancer Res; 2001 Mar; 61(6):2609-17. PubMed ID: 11289138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
    Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
    Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
    Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
    Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
    Wang LK; Kuang M; Hua YP; He Q; Chen B; Wang Y; Peng BG
    J Surg Res; 2013 Aug; 183(2):900-6. PubMed ID: 23481561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-α2b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels.
    Su Y; Cheng R; Zhang J; Qian J; Diao C; Ran J; Zhang H; Li L
    Life Sci; 2015 Dec; 143():18-26. PubMed ID: 26518164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.